Product Information
SELZENTRY 300 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $28.1311 per EA under NDC 49702022418. Its NADAC has been published 657 times since Nov 28, 2013.
FDA first approved this application on Aug 6, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the maraviroc market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
ViiV Healthcare CompanyNDC
49702022418
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
MARAVIROCApproval Type
New Drug (NDA)
FDA Application
NDA022128FDA Approved
8/6/2007
TE Code
AB
On Market Since
5/16/2011
Pharmacological Classes
Price Statistics
The NADAC for SELZENTRY 300 MG TABLET has been published 657 times since Nov 28, 2013, and over the history we have for it it has risen 61.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $28.1311 per EA |
|---|---|
| All-time high | $28.1311 (Sep 30, 2026) |
| All-time low | $17.4061 (Jan 22, 2014) |
| 52-week high | $28.1311 |
| 52-week low | $28.0198 |
| Median price | $24.9780 |
| Average price | $24.3200 |
| Largest weekly change | +7.9% (Jan 10, 2018) |
| Weeks tracked | 657 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the maraviroc market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ViiV Healthcare Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
maraviroc market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
CCR5 Co-receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SELZENTRY 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SELZENTRY 300 MG TABLET, manufactured by ViiV Healthcare Company, is $28.1311 per EA (NDC 49702022418), effective Sep 30, 2026.
How has the price of SELZENTRY 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for SELZENTRY 300 MG TABLET has risen 61.2%. It has been tracked across 657 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SELZENTRY 300 MG TABLET?
Since Nov 28, 2013, the NADAC for SELZENTRY 300 MG TABLET has ranged from a low of $17.4061 (Jan 22, 2014) to a high of $28.1311 (Sep 30, 2026), with a median of $24.9780 per EA.
Are there cheaper alternatives to SELZENTRY 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SELZENTRY 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SELZENTRY 300 MG TABLET?
SELZENTRY 300 MG TABLET (NDC 49702022418) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.